Novartis signs initial agreement to provide manufacturing capacity for Pfizer-BioNTech COVID-19 vaccine

Novartis has signed an initial agreement to leverage its manufacturing capacity and capabilities in order to address the COVID-19 pandemic by supporting the production of the Pfizer-BioNTech COVID-19 Vaccine. The agreement will see Novartis utilizing its aseptic manufacturing facilities at its site in Stein, Switzerland.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news